Logo image of ENLV

ENLIVEX THERAPEUTICS LTD (ENLV) Stock Price, Quote, News and Overview

NASDAQ:ENLV - Nasdaq - IL0011319527 - Common Stock - Currency: USD

0.975  +0.01 (+1.34%)

ENLV Quote, Performance and Key Statistics

ENLIVEX THERAPEUTICS LTD

NASDAQ:ENLV (5/23/2025, 9:30:12 PM)

0.975

+0.01 (+1.34%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.76
52 Week Low0.81
Market Cap21.44M
Shares21.99M
Float19.34M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-23 2025-05-23
IPO07-30 2014-07-30


ENLV short term performance overview.The bars show the price performance of ENLV in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 4 -4

ENLV long term performance overview.The bars show the price performance of ENLV in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ENLV is 0.975 USD. In the past month the price decreased by -0.96%. In the past year, price decreased by -30.36%.

ENLIVEX THERAPEUTICS LTD / ENLV Daily stock chart

ENLV Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.84 324.18B
AMGN AMGEN INC 13.09 146.06B
GILD GILEAD SCIENCES INC 13.87 133.68B
VRTX VERTEX PHARMACEUTICALS INC N/A 112.09B
REGN REGENERON PHARMACEUTICALS 13.28 63.52B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.72B
ARGX ARGENX SE - ADR 100.1 35.88B
ONC BEIGENE LTD-ADR 6 26.02B
BNTX BIONTECH SE-ADR N/A 23.72B
NTRA NATERA INC N/A 20.84B
SMMT SUMMIT THERAPEUTICS INC N/A 19.20B
BIIB BIOGEN INC 7.95 18.43B

About ENLV

Company Profile

ENLV logo image Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Company Info

ENLIVEX THERAPEUTICS LTD

14 Einstein St.

Ness Ziona 7403618 IL

CEO: Oren Hershkovitz

Employees: 71

ENLV Company Website

ENLV Investor Relations

Phone: 97286623301

ENLIVEX THERAPEUTICS LTD / ENLV FAQ

What is the stock price of ENLIVEX THERAPEUTICS LTD today?

The current stock price of ENLV is 0.975 USD. The price increased by 1.34% in the last trading session.


What is the ticker symbol for ENLIVEX THERAPEUTICS LTD stock?

The exchange symbol of ENLIVEX THERAPEUTICS LTD is ENLV and it is listed on the Nasdaq exchange.


On which exchange is ENLV stock listed?

ENLV stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ENLIVEX THERAPEUTICS LTD stock?

8 analysts have analysed ENLV and the average price target is 10.2 USD. This implies a price increase of 946.15% is expected in the next year compared to the current price of 0.975. Check the ENLIVEX THERAPEUTICS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ENLIVEX THERAPEUTICS LTD worth?

ENLIVEX THERAPEUTICS LTD (ENLV) has a market capitalization of 21.44M USD. This makes ENLV a Nano Cap stock.


How many employees does ENLIVEX THERAPEUTICS LTD have?

ENLIVEX THERAPEUTICS LTD (ENLV) currently has 71 employees.


What are the support and resistance levels for ENLIVEX THERAPEUTICS LTD (ENLV) stock?

ENLIVEX THERAPEUTICS LTD (ENLV) has a support level at 0.85 and a resistance level at 1.04. Check the full technical report for a detailed analysis of ENLV support and resistance levels.


Should I buy ENLIVEX THERAPEUTICS LTD (ENLV) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ENLIVEX THERAPEUTICS LTD (ENLV) stock pay dividends?

ENLV does not pay a dividend.


When does ENLIVEX THERAPEUTICS LTD (ENLV) report earnings?

ENLIVEX THERAPEUTICS LTD (ENLV) will report earnings on 2025-05-23.


What is the Price/Earnings (PE) ratio of ENLIVEX THERAPEUTICS LTD (ENLV)?

ENLIVEX THERAPEUTICS LTD (ENLV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).


What is the Short Interest ratio of ENLIVEX THERAPEUTICS LTD (ENLV) stock?

The outstanding short interest for ENLIVEX THERAPEUTICS LTD (ENLV) is 0.71% of its float. Check the ownership tab for more information on the ENLV short interest.


ENLV Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ENLV Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ENLV. No worries on liquidiy or solvency for ENLV as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ENLV Financial Highlights

Over the last trailing twelve months ENLV reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 53.21% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -63.54%
ROE -71.21%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%52.08%
Sales Q2Q%N/A
EPS 1Y (TTM)53.21%
Revenue 1Y (TTM)N/A

ENLV Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to ENLV. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners15.69%
Ins Owners5.59%
Short Float %0.71%
Short Ratio0.99
Analysts
Analysts82.5
Price Target10.2 (946.15%)
EPS Next Y18.26%
Revenue Next YearN/A